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Abstract: Breast cancer metastatic to bone has a poor prognosis despite recent advances in 
our understanding of the biology of both bone and breast cancer. This article presents a new 
approach, the ABC7 regimen (Adjuvant for Breast Cancer treatment using seven repurposed 
drugs), to metastatic breast cancer. ABC7 aims to defeat aspects of epithelial-to-mesenchymal 
transition (EMT) that lead to dissemination of breast cancer to bone. As add-on to current 
standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed 
noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and 
the added EMT occurring as a response to current treatment modalities. Chemotherapy, radia-
tion, and surgery provoke EMT in cancer generally and in breast cancer specifically. ABC7 uses 
standard doses of capecitabine as used in treating breast cancer today. In addition, ABC7 uses 
1) an older psychiatric drug, quetiapine, to block RANK signaling; 2) pirfenidone, an anti-fibrosis 
drug to block TGF-beta signaling; 3) rifabutin, an antibiotic to block beta-catenin signaling; 
4) metformin, a first-line antidiabetic drug to stimulate AMPK and inhibit mammalian target 
of rapamycin, (mTOR); 5) propranolol, a beta-blocker to block beta-adrenergic signaling; 6) 
agomelatine, a melatonergic antidepressant to stimulate M1 and M2 melatonergic receptors; and 
7) ribavirin, an antiviral drug to prevent eIF4E phosphorylation. All these block the signaling 
pathways – RANK, TGF-beta, mTOR, beta-adrenergic receptors, and phosphorylated eIF4E – 
that have been shown to trigger EMT and enhance breast cancer growth and so are worthwhile 
targets to inhibit. Agonism at MT1 and MT2 melatonergic receptors has been shown to inhibit 
both breast cancer EMT and growth. This ensemble was designed to be safe and augment 
capecitabine efficacy. Given the expected outcome of metastatic breast cancer as it stands today, 
ABC7 warrants a cautious trial.
Keywords: ABC7, breast cancer, agomelatine, capecitabine, metformin, pirfenidone, proprano-
lol, quetiapine, repurposing, ribavirin, rifabutin, TGF-beta
Plain language summary
This article presents the rationale and thinking behind the ABC7 regimen for metastatic breast 
cancer. Since there is currently no cure for breast cancer once it has spread to bone and other 
organs beyond the breast itself, the ABC7 regimen was designed to take advantage of ancillary 
attributes of seven common and readily available noncancer treatment drugs that, in theory, 
should make current traditional cytotoxic chemotherapy with capecitabine more effective. The 
ABC7 regimen has not been shown to be safe or effective yet. In the current article, we discuss 
an untested proposal for a new treatment approach to metastatic breast cancer.
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Estrogen-positive metastatic breast cancer cannot be cured 
currently.1 One major metastatic site of breast cancer is 
bone. Once breast cancer metastasizes to bone, the survival 
rate declines despite recent advances in local treatments of 
breast cancer. Current treatment strategies for bone metas-
tasis, including bone-targeted agents (bisphosphonate and 
denosumab), provide only palliation. New and effective 
therapeutic strategies for this still incurable disease are 
therefore urgently needed.
This article reviews the attributes of seven currently mar-
keted drugs that, as indicated by prior research data, will block 
or partially block the escape pathways from current traditional 
treatments. The seven drugs of ABC7 were chosen by first 
identifying the basic pathways by which EMT is initiated and 
maintained. We then reviewed 1000 of the most commonly used 
drugs2 for which we have both usual plasma levels and pub-
lished data showing potential inhibitory interaction with these 
pathways. The resulting list was reduced by semi- subjective 
evaluation of the strength of data on their EMT inhibition 
benefit versus the drugs’ expected tolerability. The better the 
tolerability, the weaker the data had to be for inclusion.
This ABC7 regimen is designed to block several core 
breast cancer growth signals in a coordinated manner, thereby 
augmenting the cytotoxicity of a currently used cytotoxic 
chemotherapy drug, capecitabine. Figure 1 shows an over-
view schematic of the biochemistry that ABC7 is designed 
to influence. This is explained in detail in the respective drug 
discussions in the “Drugs to inhibit EMT” section. Table 1 
gives an overview of the ABC7 drugs and their intended 
targets in treating breast cancer.
The ABC7 regimen follows the approach of previous 
cancer treatment regimens, for example, MTZ regimen,3 
COMBAT regimen,4 MEMMAT regimen, a current trial of 
Peyrl et al’s seven-drug cocktail (ClinicalTrials.gov Identifier: 
NCT01356290), and CUSP9 regimen.5,6 In all of the studies, 
extensive use is made of drugs not primarily marketed to treat 
cancer but that have ancillary attributes that research data 
indicate would enhance the anticancer effect of a cytotoxic, 
traditional cancer treatment drug. The ancillary drugs exert 
anticancer effects by blocking various growth-enhancing sur-
vival pathways used by the target cancer or as for agomelatine 
are agonists at growth-retarding receptors.
Similar to other cancers, breast cancer has heteroge-
neous regions within the same tumor – different areas that 
depend on or use different growth-signaling pathways. This 
is related to but distinct from the idea of clonal evolution 
driven by cytotoxic chemotherapy selection. Both forms of 
 heterogeneity exist in a typical breast cancer, proteomic and 
genomic. ABC7 aims to inhibit breast cancer by pharmaco-
logical manipulation of what genes are expressed and what 
genes are not, as well as by targeting different clonal variants 
of the original breast cancer clone.
Because of these limitations, we do not expect testing 
for molecular markers to be predictive or useful. In addition, 
further intensifying the spatial and temporal diversity of 
the molecular status, particularly for EMT markers, are the 
diversity-driving effects of chemotherapy7 and discussed in 
greater detail in the following sections.
Cytotoxic chemotherapy also induces important receptor 
status changes in a large minority of breast cancer cases.8,9 
Typical findings are as follows: 13% changed from HR+ to 
HR−, 5% changed from HR− to HR+, 6% changed from 
HER2+ to HER2, 3% changed from HER2 to HER2+, and 
13% changed to triple negative.8
Multiple signaling systems have been identified that 
drive metastatic breast cancer.1,9–11 These growth-driving 
receptors can cross cover for each other.1,9–11 When one is 
pharmacologically blocked, several parallel growth-driving 
pathways can become active, taking the place of the blocked 
pathways. Growth factor signaling converges from a wide 
variety of outer membrane receptors to more restricted, fewer, 
intracellular pathways. This is, more elegantly stated, the 
spatial–temporal genomic and proteomic range, the “genetic 
collectives [that] dominate the landscape of advanced-stage 
(malignant) disease.”11,12 We see this as mandating an inte-
grated, coordinated polypharmacy to successfully address 
these malignancy attributes.
Capecitabine is intracellularly metabolized to 5-FU; 
the details are given in the “Capecitabine: 359 Da, half-life 
<1 hour” section. ABC7 drugs are designed to make 5-FU 
more effective.
The results of several recent ER+ metastatic breast cancer 
studies are listed in Table 2. These studies cannot be judged 
simply by overall survival in that entry  requirements were 
different, with different kinds and number of prior treat-
ments. These numbers in Table 2 are for general idea only.1 
One cannot conclude that one of these is better than another.
In general, post-progression survival durations in recent 
Phase III studies of combination therapy ranged from 
approximately 16 to 33 months.1
EMT is a feature of cancers generally13 and breast cancer 
specifically.14,15
Table 3 lists several features and behaviors associated 
with the two (epithelial and mesenchymal) states. Interest-
ingly, a transcription factor ZEB1, known to control EMT, 





contributes to breast cancer osteolytic bone metastasis, but 
not brain or lung metastasis.16,17
EMT is a phase transition, where flat, sessile, mutually 
adherent epithelioid cells take on a rounded, non-adherent, 
motile mesenchymal shape and behavior.18–20 The reverseless 
transient state and process, MET, also occurs and is also a 
feature of robust or aggressive cancer growth.21 Post-EMT 
cells tend to be invasive but proliferation restricted. Post-MET 
cells tend to be proliferative but have limited invasiveness.18–20 
Breast cancers develop in proximity to adipose tissue. 
Adipocytes are a further trigger to EMT.22 The relationship 
between stem cell subpopulations within a cancer and EMT 
Figure 1 The basic biochemical, intracellular, and receptor pathways relating to interventions of the ABC7 regimen for advanced breast cancer.
Notes: This is the basic breast cancer intracellular circuitry that the ABC7 regimen attempts to address. The two major controllers or stimuli for eIF4E activation are 




































Table 1 The drugs of ABC7, their targets during treatment of breast cancer, and suggested doses
Drug Target in breast cancer treatment Starting dose Target dose
Capecitabine DNA synthesis 600 mg/m2 twice daily.
7 days on, 7 days off
1250 mg/m2 twice daily. 7 days on, 7 days off or 14 days on, 
7 off
Quetiapine RANK/RANKL 50 mg once at bedtime 300–600 mg once at bedtime
Pirfenidone TGF-beta 200 mg three times daily 600 mg three times daily
Rifabutin BCL-6; beta-catenin 150 mg/day 300 mg/day
Metformin AMPK*; mTOR; mitochondria oxphos 500 mg once daily 1000 mg twice daily
Propranolol Beta-adrenergic receptors 10 mg twice daily Uptitrate as tolerated
Agomelatine Melatonergic receptors* 25 mg once at bedtime 50 mg once at bedtime
Ribavirin** eIF4E; MNK; IMPDH 600 mg/day 1200 mg/day
Notes: The drugs are listed in a suggested order of addition. Pace of drug addition is individualized per patient and physician estimations of risk/benefit. *Note that all entries 
denote inhibition of named target except for metformin that activates AMPK and agomelatine that stimulates melatonin receptors. All drugs, except capecitabine, are given 
continuously without interruption. Capecitabine is given on 7 days on, 7 days off, or 14 days on, 7 days off cycles. **Ribavirin is likely to give unpleasant side effects and 
depressed mood but is potentially a beneficial enough drug to try.
Table 2 Representative recent trials in metastatic HR+ breast 
cancer
Intervention Months survival Trial
Anastrozole + fulvestrant 48 SWOG
Anastrozole + fulvestrant 38 FACT
Anastrozole + fulvestrant 21 SoFEA
Letrozole + fulvestrant 52 LEA
Everolimus + exemestane 31 BOLERO 2





process is also unclear,23 and the two populations probably 
largely overlap.
Perhaps our deepest insight into the EMT process in breast 
cancer came from a study by Bulfoni et al.24 They showed 
that all patients with metastatic breast cancer had CTCs. 
These circulating cancer cells split into four groups: those 
with epithelial, those with mesenchymal, those with both, 
and those with neither marker. Patients with higher numbers 
of circulating cancer cells that expressed both markers had 
shorter overall survival.
Survival as a function of E-cadherin expression, repre-
sentative of epithelial state, and fibronectin, representative of 
mesenchymal state, was examined by immunohistochemistry 
on 1495 breast cancer biopsies.25 More E-cadherin and less 
fibronectin are associated with longer survival.25 Breast 
cancer patients whose tissue expresses greater EMT-related 
protein have shorter survival.26 EMT drives chemotherapy 
resistance and other poor prognosis features in breast 
 cancer.27–29 In addition, a greater degree of metabolic changes 
characteristic of EMT in breast cancer predicts shorter overall 
survival.30
Medical research discusses vimentin, fibronectin, and 
N-cadherin as markers of EMT process, but these proteins 
would be more accurately viewed as mediators of the attri-
butes we designate EMT.
As indicated in Table 3, fibronectin is a characteristic 
marker of EMT. Higher breast cancer tissue expression of 
fibronectin correlates with shorter survival.31,32 A range of 
other characteristic behavioral and morphological attributes 
of EMT and MET states is also outlined in Table 3.
Chemotherapy triggers EMT
Paclitaxel triggers EMT in breast cancer, increasing mesen-
chymal markers, vimentin and fibronectin, and decreasing 
epithelial marker, ZO-1.33 Experimental inhibitors of TGF-
beta signaling block paclitaxel-induced EMT and suppress 
paclitaxel-induced CSC properties.33 Paclitaxel also increases 
EMT markers in mouse breast cancer cell line, MCF-7/PAX.34 
Doxorubicin exposure enhances gastric cancer’s EMT marker 
expression.35
These reports, combined with similar findings in other 
cancers, allow a general statement of a core principle of 
oncology: cytotoxic chemotherapies tend to provoke EMT. 
Such a conjecture is amply supported by the recent work 
of Yoshimasu et al36 who reported that cisplatin, 5-FU, 
 gemcitabine, paclitaxel, and vinorelbine show hormesis when 
tested individually.
Surgical trauma or fine-needle biopsy 
triggers EMT
Of concern in current medical practice, there is a tendency 
for cancers generally, and breast cancer specifically, to be 
triggered by any kind of tissue disruption – including fine-
needle biopsy – to undergo EMT with consequent cancer 
cell shedding to circulation. Such hematogenous tumor cell 
dissemination could be the origin of later overt metastases.
Breast cancers in mice release a flood of CTCs after 
simple fine-needle biopsy.37 Clinical needle biopsy of breast 
cancer triggers recruitment of inflammatory cells to the biopsy 
site and causes increased tumor cell mitoses in the biopsied 
area.38 In a second murine breast cancer study, both fine-
needle biopsy and surgical resection resulted in the release 
of a flood of CTCs, but noteworthy in this work is that biopsy 
resulted in greater and longer lasting appearance of circulat-
ing cancer cells than did surgical resection.39 These murine 
data were replicated by Kaigorodova et al40 who showed that 
simple fine-needle biopsy of human breast cancers releases 
a flood of breast cancer cells into the general circulation. 
These authors found that although some released CTCs had 
CSC markers and attributes and some did not, none of them 
had the particular EMT markers for which they were tested.
This worrisome situation in breast cancer is similar to 
data collected in other cancers. For example, treatment with 
radioactive needle insertion into prostate cancer results in 
significant hematological shedding of tumor cells post pro-
cedure.41 Standard transrectal ultrasound-guided prostate 
needle biopsy results in detectable prostate cancer cells in 
the circulation in half of patients.42 Oral squamous cell car-
cinoma biopsies result in 16% of patients having post-biopsy 
Table 3 Characteristic protein markers and mediators of EMT 
in breast cancer









Phenotype Epithelial state Mesenchymal state
Motility Sessile Motile
Shape Elongated Rounded
Adherence Adherent to neighbors Non-adherent to neighbors
Invasion Noninvasive Invasive
Proliferation Higher proliferation Lower proliferation
Microtentacles Absent Present 
Abbreviation: EMT, epithelial-to-mesenchymal transition.





CTCs.43 Simple wide excision that does not disrupt the tumor 
tissue integrity did not result in postoperative CTCs, whereas 
incisional biopsy did.44
A study is therefore required comparing the long-term 
outcome potential difference between those having fine-
needle biopsy versus those having initial wide lesion excision. 
If initial excision that leaves the suspicious mass intact does 
result in fewer later disseminated metastases, it might be 
worth the iatrogenic morbidity incurred by the consequent 
excision of some benign masses.
Radiation triggers EMT
Above we reviewed some evidence that chemotherapy and 
mechanical tissue disruption give rise to CTC and EMT in 
surviving cells. Below we review data showing radiation 
causes CTC and EMT as well.45,46 For a few specific examples, 
as in other cancers,47 breast cancers synthesize GM-CSF 
that then functions as a growth factor for them.48 Clinically 
used, radiation treatment not only kills breast cancer cells 
and prolongs survival in breast cancer but also triggers 
exposed residual cells that are not killed to undergo EMT, 
to start migrating, and to synthesize increased amounts of 
autocrine growth factor, GM-CSF.49 Radiation also increases 
IL-6, migration, and EMT markers in murine and human 
breast cancer cell lines.50 The subject of radiation-induced 
EMT and radiation-induced increase in CTCs was recently 
reviewed by Lee et al.51
Clinically, finding greater post-EMT CTCs confers a 
worse prognosis with more aggressive disease course and 
greater metastatic proclivity in colon cancer52 and finding 
circulating clusters of vimentin-positive gastric cancer cells 
confers a worse prognosis53 as did finding circulating cancer 
cell clusters and vimentin-positive CTC in colon cancer.54 
Surgery for epithelial ovarian cancer causes an increase in 
both EMT-positive and EMT-negative CTCs, but there is a 
disproportionate increase in EMT positive. The increase in 
EMT-positive CTCs was even stronger after platinum-based 
chemotherapy.7 As Kolbl et al55 point out, EMT precedes the 
release of CTCs but after entering circulation CTC can revert 
to epithelial or partial epithelial phenotype.
Based on all these evidences, it seems that inhibiting 
EMT is a worthwhile goal during breast cancer treatment 
and that current common cancer treatments have elements 
of cancer growth stimulation inherent to them, or as Niccolo 
Machiavelli (born 1469–died 1527) said in 1513:
People should either be caressed or crushed. If you do 
them minor damage they will get their revenge; but if you 
cripple them there is nothing they can do. If you need to 
injure someone, do it in such a way that you do not have to 
fear their vengeance.
ABC7 regimen was crafted with that in mind.
Drugs to inhibit EMT
Quetiapine: 384 Da, cyp3A4 to 
norquetiapine, 6-hour half-life
The RANK, its ligand (RANKL), and the soluble decoy 
receptor OPG (or bone protector) are central elements in 
breast cancer’s establishment of metastases to bone.56 Early 
indications are that quetiapine inhibits the RANK/RANKL 
signaling system.57
Several forms of pro-RANKL are expressed on osteo-
blasts. After proteolytic release, RANKL binds to RANK 
leading to osteoclast syncytium formation then osteoclasts’ 
resorption of bone. Osteopetrosis results when RANK/
RANKL system is nonfunctional. RANK/RANKL also 
functions in guiding normal breast gland ontogeny. There 
occurs an ebb and flow of RANK expression in mammary 
duct epithelial cells during the menstrual cycle, the increase 
occurring in late luteal phase. RANK/RANKL function is 
essential to the luminal epithelial proliferation seen particu-
larly where ducts branch.56 Higher levels of RANK/RANKL 
in human breast cancer biopsy tissue correlate with higher 
metastasis likelihood and shorter survival.58
PR-negative cells are affected through RANKL-induced 
paracrine actions leading to proliferation of mammary epi-
thelial PR-negative cells.59
RANK/RANKL is a core physiologic signaling system 
allowing circulating breast cancer cells to metastasize to 
bone.60,61 RANK/RANKL is a principal part of the complex 
signaling giving rise to breast cancer’s propensity to metas-
tasize to bone.
Since breast cancer commonly metastasizes to bone 
with consequent bone pain, pathological fractures, ver-
tebrae compressions, and hypercalcemia, this process is 
important to block. Breast cancer cells are continuously 
shed into circulation from the primary and metastatic 
sites. Why then do these CTCs choose to establish growth 
preferentially in bone? This is because these CTCs can 
establish growth-enhancing communication with bone 
cells, specifically osteoblasts, and they do so primarily via 
RANK/RANKL.62 Muscle, skin, liver, spleen, fat, and other 
sites of less common breast cancer metastasis cannot so 
reciprocally communicate.
Osteoblasts receiving RANKL signaling transform to 
syncytial osteoclasts that resorb bone and increase TGF-beta. 
TGF-beta is also stored in bone, then released with any bone 





dissolution. This creates room for the CTCs to grow and free 
TGF-beta signaling prompting them to do so,62,63 making the 
TGF-beta blocking drug pirfenidone, which is discussed in 
the following sections, an ideal partner drug for quetiapine 
during metastatic breast cancer treatment.
An initial dose can be 50 mg once at bedtime, uptitrating 
to a target dose of quetiapine 300 mg or more as tolerated, 
given once at bedtime. Tiredness for a few hours on awaken-
ing is common upon starting quetiapine. It then abates after 
a week or so but reappears after each dose increase. Some 
weight increase due to increased appetite can be expected. 
Otherwise, side effects are not common.
Pirfenidone: 185 Da, cyp1A2, 3-hour  
half-life
Pirfenidone is a 185 Da drug approved and marketed to treat 
idiopathic pulmonary fibrosis.64 Mild-to-moderate, reversible, 
nausea, dyspepsia, and rash are side effects in about one-third 
of treated patients, but these often resolve with continued 
use. Approximately 2403 mg/day divided into three equal 
doses is a common pirfenidone dose in treating its marketed 
indication, idiopathic pulmonary fibrosis.64,65
Pirfenidone blocks TGF-beta signaling.66–70 TGF-beta 
is a 25 kDa signaling protein proteolytically clipped from 
a larger precursor protein. Carboplatin induces elevation 
of TGF-beta and triggers EMT in NSCLC, as given in the 
“Chemotherapy triggers EMT” section,71 both effects blocked 
by coadministration with pirfenidone.71
TGF-beta signaling is a major driver of EMT in cancer 
generally72–74 and in breast cancer EMT specifically.75–78 TGF-
beta is a facilitating element of many cancers by promoting 
angiogenesis and differentiation, by immune suppression, 
by promoting loss of cell-to-cell contact, and particularly 
by promoting EMT. Pirfenidone inhibits TGF-beta-induced 
phosphorylation of SMAD3, p38, and AKT. TGF-beta pro-
vides a “get up and go” signal for breast cancer.79 In a murine 
breast cancer model, TGF-beta exposure also enhances 
 normal lung’s ability to better support establishment of breast 
cancer metastases.80 TGF-beta drives breast cancer’s EMT 
and various biochemical, morphological, and behavioral 
changes characteristic of EMT.10,81–83 The manifold paths by 
which TGF-beta signaling leads to or enhances EMT spe-
cifically in breast cancer were outlined by Tan et al,18 Chen 
et al,81 Nooshinfar et al,84 and Felipe Lima et al.75
TGF-beta dependency for taking on typical mesenchy-
mal morphology, increased motility, and increased vimentin 
expression after radiation exposure was shown in breast, 
colon, and lung adenocarcinoma cell lines.85
Preclinical studies have shown activity in pirfenidone’s 
enhancing cisplatin cytotoxicity to NSCLCs.86 In addition, 
pirfenidone enhances radiation and sunitinib cytotoxicity in 
Lewis lung cancer cells87 and reduces desmoplasia in pan-
creatic cancer.88 Growth of human TNBC tissue (ER nega-
tive, PR negative, HER2 negative) xenografted to nude mice 
was inhibited more by pirfenidone and doxorubicin than by 
doxorubicin alone.89 In another murine breast cancer model, 
pirfenidone reduced intratumoral collagen and hyaluronan 
by TGF-beta inhibition with consequent improvement of 
doxorubicin efficacy.90
Pirfenidone disrupts Hh signaling in parallel with TGF-
beta inhibition, a worthwhile added benefit during breast 
cancer treatment.91
The starting dose of pirfenidone is 267 mg three times a 
day. This is gradually increased at 14-day intervals as toler-
ated to 801 mg three times daily. Pirfenidone at 400 mg three 
times daily (1200 mg/day) used to treat potential progression 
of hepatitis C-related fibrosis reduced circulating TGF-beta 
and IL-6.92 Abdominal pain, rash, and nausea were seen in a 
half of treated patients, but these side effects tended to subside 
within a month or two and no patient dropped out due to them.
Ribavirin: 244 Da, 6-day half-life for a 
single oral dose, up to 12 days after 
continuous use
Since its introduction to clinical practice in the late 1970s, 
ribavirin had been used to treat various viral infections, later 
becoming central to a now-outmoded hepatitis C treatment. 
Ribavirin remains useful in treating human respiratory syn-
cytial virus infections and selected other rarer virus infec-
tions such as those of the hantavirus group.93 Ribavirin is 
currently being investigated in numerous clinical trials for 
its therapeutic activity in various cancers, particularly acute 
myeloid leukemia (NCT02109744, NCT02073838), head 
and neck cancer (NCT01268579), and notably for ABC7, 
metastatic breast cancer (NCT01056757).
Although ribavirin’s mechanisms of antiviral and anti-
cancer action are uncertain and probably will vary between 
viruses, several potential mechanisms of action have been 
identified. One proposes that ribavirin enters the cell via a 
nucleoside transport mechanism, intermingling itself within 
the viral RNA, thus inhibiting/altering viral RNA synthesis. 
However, ribavirin, particularly when paired with interferon-
alpha, activates anti-inflammatory responses in various other 
ways. Alternatively, due to the fact that ribavirin is structur-
ally analogous to GTP, a purine nucleoside, ribavirin can be 
incorporated into the cell passively, thereafter competitively 





binding to, and inhibiting, RNA polymerase, and RNA syn-
thesis as a whole; ribavirin often achieves this via blocking the 
IMPDH pathway, among other pathways such as the eIF4E 
pathway. Ultimately, five major mechanisms of action have 
been proposed:94–96
1. Immunostimulation by upregulating cytokines to shift 
Th1/2 cell balance to Th1 dominance.
2. Inhibition of 24 kDa eIF4E function, thereby inhibiting 
mRNA capping and translation initiation.
3. Modulation of interferon-alpha-related gene expression.
4. Direct inhibition of IMPDH with consequent depletion 
of intracellular GTP.
5. After triphosphorylation, ribavirin triphosphate is incor-
porated into replicating RNA viral RNA polymerases with 
consequent induction of viral mutagenesis.
How ribavirin acts vis-a-vis eIF4E is as follows:
eIF4E forms part of the multimeric cap-dependent mRNA 
translation initiation complex. Mammalian cap-dependent 
translation starts with that complex binding to an RNA 
methyl-nucleotide. eIF4E has many positive and negative 
control points, two of which are 1) posttranslational phos-
phorylation and 2) 4E-BPs.97–99 There are several variants of 
4E-BP protein, hereafter designated simply as 4E-BP. 4E-BP 
is in turn controlled by its phosphorylation status.
eIF4E non-covalently bound to 4E-BP is inactive in 
translation initiation. Both currently recognized complexes 
of mTOR (mTORC1, loosely associated with growth and 
mTORC2, loosely associated with cell survival and apoptosis 
resistance) can phosphorylate 4E-BP.100 Unphosphorylated 
4E-BP has non-covalent affinity to and prevents transcription 
initiation activity of eIF4E. When phosphorylated, 4E-BP1 
loses that affinity and separates from eIF4E, thereby allowing 
eIF4E to function in cap-dependent mRNA translation.97,99–101
MAP kinase interacting kinases (hereafter referred to 
as MNK) can also phosphorylate 4E-BP, releasing it from 
eIF-4E.99,102–105 A wide variety of internal and extracellular 
events converge on mTOR and/or MNK to enhance or inhibit 
their activity. Development of resistance to mTOR inhibitors 
such as everolimus is often caused by eIF4E amplification 
or MNK upregulation.97,105
eIF4E overexpression has been identified in 30% of 
human cancers generally,97,106–110 including in invasive 
breast cancer where the degree of eIF4E, both gene and 
protein overexpression, has been positively correlated with 
occurrence, recurrence, and metastasis.111–118 eIF4E protein 
expression was associated with shorter survival, higher tumor 
mitotic index, and higher-grade breast cancer.115 Increased 
phosphorylated 4E-BP confers a worse prognosis and faster 
disease progression in breast, ovary, and prostate cancers.103
A crucially important oddity of eIF4E in breast cancer 
is the homogenous spatial uniformity of phosphorylated 
eIF4E protein overexpression in breast cancer tissues, both 
metastatic and primary.116 This is particularly notable given 
the spatial heterogeneity of ER, PR, HER2, mTOR, and other 
commonly overexpressed markers in breast cancer.
In addition, in 200 patients with Stage 4 breast cancer, 
immunohistochemistry analysis revealed that greater increase 
in eIF4E phosphorylation in response to chemotherapy with 
doxorubicin, cyclophosphamide, or FU was correlated with 
shorter median overall survival,114 4.7 years in patients with 
a two- to fourfold increase in eIF4E phosphorylation versus 
3.1 years in patients with a 9–11-fold increase. A second 
study a few years later found similar results.118 Among 
patients undergoing primary debulking for a node-positive 
breast cancer when nodes were positive, after 4-year follow-
up, systemic recurrence occurred in 22% of women with low 
eIF4E protein expression, 27% of the intermediate group, 
and in 49% expressing large amounts of eIF4E.119 Even more 
serious was the presence of multiple distant metastases in 
60% of women whose primary expressed large amounts of 
eIF4E but in 15% of women whose primary expressed low 
amounts of eIF4E, again after 4-year follow-up.119
In an unusually exciting and instructive study, Li et al120 
studied breast cancer biopsy tissue by immunohistochemistry 
both before and after chemotherapy. After cytotoxic chemo-
therapy with doxorubicin, or cyclophosphamide or 5-FU, the 
expression of phosphorylated eIF4E increased in the posttreat-
ment biopsy material, as given in the “Chemotherapy triggers 
EMT” section, and chemotherapy-activated Wnt/beta-catenin, 
as given in the “Rifabutin: 847 Da, 2-day half-life” section, 
signaling in a phosphorylated eIF4E-dependent manner.120
Although the significance of eIF4E phosphorylation or 
its range of functions is not fully understood, some aspects 
are predominantly the empirical data in the abovementioned 
paragraph. Regulation of eIF4E function is partly achieved 
through this phosphorylation process. Untreated GBMs show 
an excess of phosphorylated (unbound) 4E-BP.98,102 Inhibi-
tion of 4E-BP phosphorylation with consequent retention 
of its association with 4E-BP leads to inhibition of protein 
synthesis, inhibition of glioma cell proliferation in vitro, 
and tumor growth in vivo, in an orthotopic GBM mouse 
model.98,102 We know ribavirin gets good brain tissue levels 
based on the psychiatric morbidities associated with its use in 
treating hepatitis C. Volpin et al121 suggested using ribavirin 
to treat GBM based on these considerations.





That metformin inhibits 4E-BP1 phosphorylation via 
mTOR inhibition122 makes metformin a good coordinated 
partner drug to ribavirin. That ribavirin also inhibits MNK and 
since MNK phosphorylation of eIF4E is an alternate eIF4E 
activation pathway particularly used during the development 
of resistance to the mTOR inhibitor  everolimus,98,99,102,123,124 
ribavirin might be combined with everolimus or metformin 
to advantage. This would be a good example of the phenom-
enon mentioned in the “Introduction” section that when one 
growth pathway is pharmacologically blocked other paral-
lel growth-driving pathways can become active, taking the 
place of blocked paths. mTOR phosphorylates 4E-BP1, or if 
mTOR is inhibited then MNK can take over, phosphorylat-
ing 4E-BP1. This would also explain why and how mTOR 
inhibitors have not been successful in treating some tumors 
such as GBM even though they express an overabundance 
of mTOR. MNK simply takes over when mTOR is blocked.
TGF-beta promotion of EMT that occurs largely through 
phosphorylation of eIF4E by MNK (with multiple intermedi-
ates between the two)103 makes pirfenidone a good partner 
drug for both metformin and ribavirin.
In addition, experimental MNK inhibitors decrease eIF4E 
phosphorylation levels in breast cancers,120 and GBM,98 
where MNK inhibition enhanced temozolomide cytotoxic-
ity. In parallel fashion, in 103 cases of astrocytomas, high 
expression of phosphorylated eIF4E was significantly cor-
related with shorter overall survival rates.107
All treated breast cancers were found to overexpress phos-
phorylated (activated) eIF4E,116,120 a remarkable and unique 
finding in any cancer. Decreased eIF4E phosphorylation in 
breast cancer also resulted in increased E-cadherin and beta-
catenin protein levels125 reflecting a shift from mesenchymal 
toward epithelial attributes. The abovementioned combined 
data suggest that ribavirin could be of potential benefit by 
inhibiting eIF4E in breast cancer. Kentsis et al126,127 have 
demonstrated that ribavirin inhibits m7G mRNA cap binding 
to eIF4E. Ribavirin directly bound to eIF4E with a micro-
molar affinity at the functional site used by m7G mRNA cap, 
reducing eIF4E/mRNA binding and disrupting the translation 
process. Of note, not all mRNA translation is eIF4E depen-
dent, but important mRNAs in breast cancer are, for instance, 
the one coding cyclin D1/3, c-Myc, VEGF, FGF2/4, and 
MCL-1. Some preclinical studies in several murine models 
of breast cancer revealed that ribavirin inhibits breast cancer 
cell proliferation through eIF4E blockage.128,129 Moreover, in 
these studies, multiple-aspect characteristics of EMT were 
reversed or diminished by ribavirin.128,129
More recently, two studies demonstrated significant 
glioma cell killing by ribavirin,121,130 confirming a 2014 study 
showing that ribavirin induced G0/G1 arrest in seven glioma 
cell lines at a median 55 µM IC
50
 (range 28–664).131 This lat-
ter study positively correlated mRNA expression of PDGF 
receptor-alpha, a major driver of GBM growth, with better 
glioma cell sensitivity (lower IC
50
) to ribavirin. That PDGF 
receptor is also a major driver of breast cancer132,133 and can 
cross cover for the ER134,135 forming one of the many escape 
paths from aromatase inhibitor suppression of breast cancer 
growth. This fact favors the possibility of this path contribut-
ing to ribavirin’s inhibitory effect in breast cancer as well.
Similar to the abovementioned data on breast cancer, 
targeting eIF4E using ribavirin to block migration and EMT 
in NSCLC has been highlighted.136 In this study, inhibition 
of eIF4E after ribavirin treatment led to decreased migra-
tion, differentiation, and expression of several EMT-related 
genes such as ERa, SMAD5, NF-kB, cyclin D1, c-MYC, or 
HIF-1a.136 As we expect to do but using ribavirin, an engi-
neered short hairpin RNA interfering with eIF4E transcrip-
tion inhibited breast cancer cell migration, primary tumor 
growth, and metastasis establishment.137
TGF-beta-induced eIF4E phosphorylation enhanced 
metastases, invasion, and EMT in a mouse breast cancer model, 
all of which were inhibited when an  un-phosphorylatable 
eIF4E was present.138
IMPDH is a pivotal enzyme for biosynthesis of GTP and 
is frequently increased in tumor cells.139 It has been shown 
that ribavirin via IMPDH inhibition was effective against 
chronic lymphocytic leukemia cells.140 Recently, Isakovic 
et al130 demonstrated in glioma cells that ribavirin inhibits 
IMPDH activity and induces autophagy inhibiting the activity 
of mTORC1 and the SRC/AKT pathway.
Of deep significance for understanding breast cancer 
growth and the ABC7 regimen to inhibit it, is the study by 
Decarlo et al,141 where they demonstrated a feed-forward 
amplification loop between TGF-beta and eIF4E (that we 
intend to block with pirfenidone and ribavirin, respectively). 
In addition, TGF-beta agonism drives eIF4E activation138 
confirming pirfenidone as a good partner drug for ribavirin.
Ribavirin has also been shown to inhibit mTOR/eIF4E 
signaling increasing paclitaxel and imatinib activity in squa-
mous cell carcinoma142 and leukemic cells,124 respectively.
Discussion here of ribavirin strikes at the heart of why 
pharmaceutical mTOR inhibitors such as everolimus have 
not been as clinically useful as the biochemistry of cancer 
indicates it should be. The data in this section paint a con-
sistent picture of eIF4E as a central element in breast cancer 
malignancy degree and as such a worthwhile target to inhibit. 
Ribavirin can be expected to do this effectively but it will be 
the most difficult of the ABC7 drugs to tolerate. Ribavirin is 





the problematic drug of ABC7. When used over months to 
treat hepatitis C, 1000 mg/day would have been a common 
dose. Depressed mood, anemia, weight loss, and a severe but 
ill-defined malaise were common side effects and not rarely 
required dose reduction or even stopping ribavirin entirely.143 
Given ribavirin’s propensity to give unpleasant side effects, 
it should be increased with caution from starting dose of 
100 mg once daily with frequent mood and CBC evaluations.
Rifabutin: 847 Da, 2-day half-life
Rifabutin is an old antibiotic closely related to the even 
older drug rifampin (same as rifampicin). Rifabutin is active 
against Mycobacterium tuberculosis, atypical mycobacteria, 
staphylococci, group A streptococci, Neisseria gonor-
rhoeae, Neisseria meningitidis, Haemophilus influenzae, 
 Haemophilus ducreyi, Campylobacter spp., Helicobacter 
pylori, chlamydia, and Toxoplama gondii.144,145
In 2016, rifabutin was reported to have blunted the growth 
of a patient’s NSCLC, subsequently studied in vitro and 
found to be active in inhibiting lung cancer cell growth and 
suppressing Ki67 staining.146 Rifabutin suppressed eIF4E 
phosphorylation with consequent decreased beta-catenin 
phosphorylation and increased beta-catenin destruction 
consequent to that.146 Thus, rifabutin could coordinate to 
advantage with ribavirin to thoroughly block eIF4E.
Erlotinib inhibits epidermal growth factor receptors 
(HER1, EGFR) and is effective initially in stopping some 
lung cancers’ growth. As resistance to erlotinib develops, 
EGFR mutations resulting in EGFR affinity to beta-catenin, 
thereby shifting growth drive to beta-catenin system.147,148 
eIF4E–beta-catenin axis is inhibited by several of the ABC7 
drugs.
BCL6 is a 95 kDa protein transcription factor of selected 
genes, inhibiting expression of some and triggering transcrip-
tion of others’ in cancers generally149 and in breast cancer 
specifically.150–152 The result is a BCL-6-mediated anti-
apoptosis effect. Breast cancer cells’ survival is enhanced by 
BCL6.151 Rifabutin binds to BCL6, preventing its function 
in translation inhibition.153 This would be expected to be of 
benefit on multiple accounts during breast cancer treatment. 
Interestingly, miR-544 inhibition of BCL6 in TNBC cells 
inhibited proliferation, migration, and invasion in vitro.154 
BCL6 promoted invasion, migration, and EMT marker 
expression in breast cancer with indication that greater 
expression of BCL-6 correlates with shorter overall survival 
in breast cancer.150
Not all malignant cells within a strongly ER+ breast can-
cer will express ERs. The minority population not expressing 
ERs is relatively chemotherapy resistant with some of that 
extra chemotherapy resistance mediated by upregulated 
BCL-6 specifically in that subpopulation.155
Metformin: 129 Da, not metabolized, 
6-hour half-life
Metformin is the most prescribed initial drug treatment 
for type 2 diabetes worldwide. Despite 60 years of use, 
the mechanism of action in lowering average glucose is 
not entirely clear.156 Hepatic gluconeogenesis is decreased 
by metformin and insulin sensitivity is increased but how 
that occurs is uncertain. Metformin in vivo and in vitro 
increases AMPK, a major regulator of energy homeostasis, 
metabolism, and protein synthesis.156 Thus, activated AMPK 
results in inhibition of mTOR. Breast cancer cell expression 
of beta-catenin was decreased by metformin concomitantly 
and proportionately to AMPK phosphorylation.157
Decreased insulin/insulin-like growth factor-I signaling 
and inhibition of mitochondrial electron transport chain 
complex are other documented actions of metformin. Across 
many cancers, a large chart review has shown decreased mor-
tality in patients treated with metformin.158 Experimental data 
support the notions that increased lactate secretion, reduced 
oxygen consumption, and activated AMPK signaling are 
plausible mechanisms for metformin’s anticancer effects.159 
Metformin also decreased breast cancer cells’ intracellular 
adenosine triphosphate, viability, and anti-apoptotic protein 
BCL6 concomitant with increased intracellular ROS,160 the 
conclusion being that metformin acts primarily on mito-
chondria, other effects being secondary to that. That work 
confirmed a related earlier breast cancer study where the 
mode of viability loss mediated by metformin was found to 
be by oxidative stress increase and BCL-2 decrease.161
Silvestri et al162 showed that metformin was indeed 
cytotoxic to breast cancer cells but 1) only in low glucose 
conditions – high glucose in vitro could subvert metformin’s 
growth inhibition and 2) although AMPK activation was a 
requirement for cytotoxicity, mTOR was not. However, Wu 
et al163 showed that metformin both increased lifespan of 
the nematode Caenorhabditis elegans and showed growth 
inhibition of pancreatic cancer and melanoma cells by an 
AMPK-independent interference with mitochondrial respira-
tion mechanism. Likewise, Ben Sahra et al164 demonstrated 
that metformin cytotoxicity to androgen-sensitive human 
prostate adenocarcinoma cells was AMPK independent but 
mTOR inactivation dependent. Furthering complicating 
delineation of metformin’s mechanism of action in treating 
cancer, Gui et al165 showed that metformin’s anticancer effect 





was by inhibiting mitochondrial regeneration of oxidized 
NAD+ regeneration and lowering aspartate levels.
Just in 2016, five extensive reviews appeared recounting 
evidence favoring the use of metformin as treatment adjunct 
in cancer generally.166–170
In a study particularly relevant to ABC7 regimen consid-
ering that capecitabine metabolizes into 5-FU within cancer 
cells, Qu et al171 showed that breast cancer cells that had 
become resistant to 5-FU regained cytotoxic sensitivity to 
5-FU by simultaneous exposure with metformin. Metformin 
synergy with 5-FU could also be demonstrated to breast 
cancer cells in both the stem and non-stem subpopulations.172 
Of central importance to the ABC7 regimen, IC
50
 of 5-FU 
to esophageal cancer cells was lowered by metformin173 and 
correlated with increased AMPK activation and decreased 
mTOR function and lactate production. Metformin plus 
5-FU combination was also active in slowing esophageal 
cancer growth in a xenotransplant model more than either 
agent alone.174
YAP is a small protein transcription factor promoting the 
growth of many cancers. When phosphorylated, it is retained 
in cytoplasm and therefore nonfunctional in promoting 
growth or inhibiting apoptosis. Metformin treatment of hepa-
tocellular carcinoma patients increased YAP phosphorylation 
via AMPK phosphorylation and prolonged survival, half 
deceased at ~31 months without compared to ~44 months 
with metformin.175 Adding metformin to exemestane also 
increased survival in ER+ breast cancers that overexpressed 
IGF1R.176
An ongoing trial (ClinicalTrials.gov Identif ier 
NCT01589367) is studying potential survival benefits of 
adding metformin 2000 mg/day to standard antiestrogen 
aromatase inhibitor, letrozole 2.5 mg/day, in nondiabetic 
postmenopausal women with ER+ breast cancer.
Preoperative treatment of breast cancer patients with met-
formin has given mixed results. Some studies showed reduced 
mitotic rate after metformin 2000 mg/day177 and 1500 mg/
day,178 while others showed no reduction using 1500 mg/
day.179 A similarly designed study using 1700 mg/day found 
marginally lower Ki67 only in women with increased insulin 
resistance.180
A pivotal study supporting metformin use during the 
treatment of breast cancer was reported back in 2011. In 
women undergoing primary resection for breast cancer, 1 g 
twice daily metformin was given 14 days prior to surgery.177 
By immunohistochemistry, the diagnostic biopsy was com-
pared to resected tissue for p-AMPK, p-AKT, insulin recep-
tor, cleaved caspase-3, and Ki67. In metformin  pretreated, 
increased p-AMPK and decreased p-AKT were seen com-
pared to those not treated with metformin in the interval 
between biopsy and surgery. Ki67 and cleaved caspase-3 
were diminished in metformin-treated women compared to 
those not so treated. These changes were not large but were 
statistically significant and large enough to expect some 
clinical benefit.177
Although metformin decreases breast cancer cell survival 
in vitro,160–162,181 the clinical benefit would seem small given 
the equivocal human trials and evidence that the small benefit 
seen tended to be restricted to diabetic/prediabetic people. 
However, small benefit is not no benefit.
Metformin despite being hydrophilic achieves approxi-
mately equal plasma and brain tissue levels. In rats, after 
single-dose oral metformin administration, 28 µmol/L plasma 
and 14 nmol/g brain tissue (14 µM) were seen.182 Average 
metformin plasma levels typically seen in asymptomatic 
diabetes patients were 2.7 ± 7.3 mg/L, ~3 µM. The unusu-
ally wide drug range seen, ± 7.3 mg/L (± 57 µM), reflects 
metformin’s safety.183 Metformin’s side effects are limited to 
diarrhea, nausea, and vomiting. Some cases of lactic acidosis 
could occur but at a low frequency and when metformin is 
implicated as the cause of lactic acidosis, metformin plasma 
levels greater than 5 µg/mL are generally found. Target dose 
of metformin is the standard dose used in past breast cancer 
studies of metformin – 1700–2000 mg/day.
Propranolol: 259 Da, cyp 1A2, 2D6, 
9-hour half-life
Propranolol was the first beta-blocker introduced to clinical 
practice. Introduced in the 1960s, it is still in wide use to 
treat hypertension, migraine, angina, selected arrhythmias, 
essential tremor, resolution of infantile hematomas, and 
in reducing the cardiac effects (tachycardia) due to acute 
anxiety. Propranolol’s general cancer process inhibiting 
attributes were recently reviewed.184 Below are selected data 
supporting propranolol’s use specifically as adjunct in breast 
cancer treatment.
A study of 404 breast cancer patients to compare the 
proliferation rates of breast cancers in women who had 
taken beta-blockers compared to those who had not found a 
clear reduction in Ki67 only in those with Stage 1 disease.185 
A single ER+, HER2− patient was treated with 25 days of 
propranolol 1.5 mg/kg per day after diagnostic biopsy but 
before resection. Resection of tumor tissue showed a 23% 
reduction in Ki67 staining compared to biopsy tissue 25 days 
earlier, before any propranolol.185 Of important note, beta-
1-selective beta-blockers did not work to reduce Ki67, only 





nonselective beta-blockers did. However, a large European 
epidemiological study found no survival benefit from pro-
pranolol use after a breast cancer diagnosis.186
Of particular interest to ABC7 regimen, Rico et al187 
examined the effects of metformin and propranolol singly 
and combined in several preclinical TNBC models, finding 
additive to synergistic growth-inhibiting effects.
In a cohort of 800 women with early TNBC, 9% used 
beta-blockers. The beta-blocker use and nonuse groups were 
well matched. At 5 years, 19% of the nonusers had died of 
breast cancer while 8% of beta-blocker users had died of 
breast cancer.188
In examining a cohort of 1971 multiple myeloma patients, 
those who took any beta-blocker, had a 24% disease-specific 
mortality at 5 years. Those who took a beta-blocker plus other 
cardiac drugs had 32% while those on no cardiac or blood 
pressure medicines had 41% myeloma-specific mortality at 
5 years.189
An interesting study from Choy et al190 showed that among 
1000 breast cancer patients those on a beta-blocker had a 
lower recurrence rate, and specifically TNBC expressed par-
ticularly high levels of beta-adrenergic receptors. Their brain 
metastases expressed more beta-adrenergic receptors per cell 
than did the primary tumors.190 This study also gave evidence 
of propranolol’s inhibition of proliferation and migration in 
breast cancer cells expressing the beta-adrenergic receptor.
In reviewing seven epidemiological studies prior to 
2015 on beta-blocker use in breast cancer, Childers et al191 
concluded that, although results were mixed between these 
studies, slightly lower risk of death was associated with beta-
blocker use. Beta-blocker use is associated with improved 
relapse-free survival (but not in overall survival) also in 
patients with TNBC.192
Bone is richly supplied with sympathetic nerve endings. 
When specifically osteoblasts’ beta-adrenergic receptor is 
stimulated by norepinephrine from these nerve endings, the 
osteoblasts secrete RANKL.193 Thus, propranolol should 
harmonize with quetiapine (vide supra) in treating and 
preventing bone metastases in breast cancer. CA125 is a 
high molecular weight mucin commonly elevated in ovarian 
cancer. Patients given perioperative propranolol showed an 
83% CA125 decrease on postoperative day 7 when those 
given placebo had a 72% decrease.194
Although the data were mixed, a review of 10 studies com-
pleted by 2015 of beta-blocker use in breast cancer concluded 
that specifically propranolol use was indeed associated with 
slightly reduced breast cancer-specific mortality.195
Propranolol-blocked beta-adrenergic agonist induced 
increased migration and decreased breast cancer cell-to-cell 
adhesion.196 Propranolol inhibited breast cancer cell migration 
in vitro.197 Breast cancer cells express beta-adrenergic receptors. 
Blocking these with propranolol lowers their glucose uptake.198
Campbell et al199 demonstrated that beta-adrenergic 
stimulation of bone increased osteoblasts’ RANKL expres-
sion. That induced RANKL increased breast cancer establish-
ment of metastases in bone.199 Thus, the combination with 
quetiapine might be particularly beneficial.
Beta-adrenergic stimulation did not change the growth 
of an orthotopic murine breast cancer but did induce a 
remarkable 30-fold increase in metastases, an effect partially 
blocked by propranolol.200 Of clinical importance to ABC7, 
Shaashua et al201 showed that combining propranolol with 
a COX-2 inhibitor in perioperative breast cancer decreased 
EMT, serum IL-6, and C-reactive protein levels.
There is risk of symptomatic iatrogenic hypotension with 
propranolol. The propranolol dose must therefore be slowly 
uptitrated as tolerated, monitoring blood pressure.
Capecitabine: 359 Da, half-life <1 hour
Capecitabine is a 359 Da pro-drug giving rise to intracellular 
release of 130 Da 5-FU.202,203 5-FU inhibits thymidylate syn-
thase, which mediates the synthesis of thymidine monophos-
phate, the active form of thymidine required DNA synthesis.
Despite ~20 years of clinical use in treating breast cancer, 
there remains some unclarity on the ideal dosing schedule for 
capecitabine.204–206 A comparison of cycles of 1000 mg/m2 
twice daily for 14 days, 7 days off with 1250 mg/m2 twice 
daily for 14 days, and 7 days off indicated lower side effect 
burden with 1000 mg/m2 twice daily.207,208
Several reports indicate that dosing capecitabine at just 
high enough level to generate palmar–plantar erythrodyses-
thesia might be most effective dosing regimen.206,209 This 
would be analogous to erlotinib dosing where titrating to 
rash might be most effective.210
Capecitabine is best given with Coke™ or fresh squeezed 
lemon juice to assure low enough gastric pH for adequate and 
uniform absorption. This would be particularly important for 
those on proton pump inhibitors.
Principle toxicity is palmar–plantar erythrodysesthesia 
(synonyms hand-foot syndrome or chemotherapy induced 
acral erythema), diarrhea, and nausea, although cytopenias, 
fatigue, dyspnea, or cardiac abnormalities can be seen.211 The 
common dose for capecitabine in breast cancer is 1250 mg/m2 
orally twice daily for 14 days, none for 7 days, every 21 days.





Agomelatine: 243 Da, 2-hour half-life
Agomelatine is a 243 Da pharmaceutical melatonergic ago-
nist at both melatonin’s receptors, M1 and M2.212 It has many 
advantages over the use of melatonin itself213,214 In short, 
these advantages are: 1) agomelatine is Health Canada and 
EMA approved and marketed as an antidepressant. As such, 
it is a well-standardized product, as opposed to over-the-
counter melatonin preparations which are exempt from the 
strict standards of approved medicines; 2) agomelatine has 
considerably tighter affinity to both M1 and M2 receptors 
than does the natural ligand (melatonin); 3) agomelatine has 
a much longer dwell time in the body than does melatonin, 
and; 4) absorption is more uniform and reliable than is 
absorption of melatonin.
Although agomelatine is available for import into the 
USA, it is not FDA approved. Ramelteon is an equally 
potent melatonergic agonist at M1 and M2 as is agomelatine. 
Ramelteon is FDA approved and marketed in the USA. It 
has similar actions and advantages over melatonin as does 
agomelatine213,215 and can be substituted for agomelatine in 
the ABC7 regimen.
Elevation of hepatic transaminases is of potential concern 
when using agomelatine. This requires regular monitoring. 
Elevation is dose dependent, occurring in ~3% of those 
receiving 50 mg once at bedtime.216 It is usually reversible.
Work pointing to diminished breast cancer cell malignant 
behavior during exposure to melatonin dates back at least 
3 decades.217 There are numerous studies about oncostatic 
effects of melatonin on several tumors as well as recent 
reviews summarizing the different mechanisms of cancer 
inhibition by melatonin.84,218–221 These include regulation of 
estrogen pathway, melatonin as SERM and SEEM, modula-
tion of the cell cycle, differentiation and the induction of 
apoptosis, inhibition of telomerase activity, inhibition of 
oxidative stress, inhibition of angiogenesis, regulation 
of circadian rhythms, avoidance of circadian disruption, 
inhibition of tumor metastasis, invasiveness and motility 
decline, and enhancement of immune system and epigenetic 
regulation.218,221
Briefly and empirically, melatonin has readily demonstrable 
growth-inhibiting effects in both in vivo animal models, with 
chemically induced mammary tumors in rodents, and in vitro 
assays in estrogen-positive human breast cancer cells.221–224 
Melatonin inhibits invasive and metastatic properties of human 
breast cancer cells in different xenograft models.225–228 Due to 
the broad spectrum of melatonin’s actions, the mechanisms 
through which it interferes with metastases are varied. These 
include modulation of cell–cell and cell–matrix interaction, 
extracellular matrix remodeling by matrix metalloproteinases, 
cytoskeleton reorganization, EMT, and angiogenesis.229
Melatonin shifts human breast cancer cells to a lower 
invasive status by upregulating E-cadherin and β1-integrin 
expression and decreasing OCT4, N-cadherin, and vimen-
tin.219,227,228,230 These findings suggest that melatonin modu-
lates both cell–cell and cell–matrix interactions in breast 
cancer and reduces the metastatic potential of the tumor. 
Melatonin also has regulatory actions on matrix metallopro-
teinases in breast cancer. It has been described that melatonin 
inhibits the induction, catalytic activity, and expression of 
MMP-9 and MMP-2.229,231 In addition to modulating the 
metalloproteinase activity, melatonin reduces cancer cell 
migration through the downregulation of ROCK-1 and 
MCLCK, two kinases that control the cytoskeletal rearrange-
ment associated with cell–cell and cell–matrix adhesion.229,232 
The attenuation of HER2-Rsk2 signaling by melatonin plays 
a main role in the melatonin-mediated suppression of EMT 
and late-staged metastasis in breast cancer cells.226,229
In tumor angiogenesis, there is a crosstalk between 
cancer cells and surrounding endothelial cells. Melatonin 
interferes in the paracrine interactions between malignant 
epithelial cells and proximal endothelial cells through a 
downregulatory action on VEGF expression in human breast 
cancer cells, which decrease the levels of VEGF around 
endothelial cells.230,231 In addition, melatonin directly exerts 
antiangiogenic actions by reducing endothelial cell prolif-
eration, invasion, migration, and tube formation, through 
a downregulation of VEGF  expression.219,233–235 Melatonin 
also impedes the EMT process and cancer cell dissemination 
through downregulatory actions of the p38 pathway227 and 
interferences with NF-κB signaling in tumor cells.217,229,236
Recently, a review of the effects of melatonin and che-
motherapeutic agents in combination in cancer treatments 
has been published.237 Although the information available is 
limited, the results obtained suggest that melatonin sensitizes 
tumor cells to the cytotoxic effects of chemotherapeutic 
agents.
In addition, in a rat ER+ breast cancer model, melatonin 
reduced tumor weight, prolonged survival, and increased 
E-cadherin without giving apparent side effects.238 In this 
model, doxorubicin cytotoxicity to the breast cancers was 
augmented by giving simultaneous melatonin.238 Melatonin 
reduced in vitro migration and in vivo growth, proliferation 
index, and metastases in a murine xenograft model.232
Of particular relevance to ABC7, earlier in year 2017, 
melatonin was shown to increase 5-FU inhibition of colon 
cancer cell proliferation, in vitro colony formation, migration, 





and invasion, showing a corresponding in vivo synergy with 
5-FU in colon cancer tumor growth inhibition in a xenograft 
model.239
Similarly, melatonin moderately enhanced cytotoxicity 
to cisplatin and doxorubicin, while slightly but significantly 
enhancing 5-FU cytotoxicity to HeLa cells.240 In an in 
vitro study, in rat pancreatic adenocarcinoma, melatonin 
augmented cytotoxicity of 5-FU, cisplatin, and doxorubi-
cin.241 Melatonin decreased pancreas cancers in hamsters 
given a carcinogen (N-nitrosobis (2-oxopropyl) amine), as 
did capecitabine. Giving both melatonin and capecitabine 
decreased this incidence further.242 Melatonin augmented 
doxorubicin cytotoxicity to lymphocytic leukemia cells 
without having cytotoxicity to normal lymphocytes.243
Melatonin sensitized human breast cancer cells to radiation 
via 1) reduction in estrogen-synthesizing proteins, and 2) induc-
tion of a twofold change in p53 expression, and 3) downregula-
tion of proteins involved in double-strand DNA break repair, 
such as RAD51 and DNA-PKcs.244 Melatonin enhanced cyto-
toxicity of 5-FU to esophageal squamous carcinoma cells both 
in vitro and in a xenograft model.245 These authors used 20 mg/
kg per day melatonin in the xenograft model, corresponding to 
a nominal 1400 mg/day for a 70 kg adult human. The common 
over-the-counter melatonin used is 3–20 mg once at bedtime. 
The tighter affinity to melatonin receptors and much longer 
half-life of agomelatine compared to melatonin would go some 
of the way toward generating a stronger agonist signal to M1 
and M2 than today’s  commonly used melatonin doses. Another 
felicitous aspect of melatonergic agonism is a potential increase 
in NK cell numbers and function.246
A remarkable epidemiological study of cancer-free 
postmenopausal women showed that higher urinary mela-
tonin levels were associated with a slightly reduced risk of 
later developing breast cancer,247 although these data are not 
uncontested. A review of all studies on urinary melatonin 
would indicate that this matter remains unsettled.248
The suggested dose of agomelatine is 50 mg once at bed-
time, twice the EMA and Health Canada recommended dose 
for treating depression. If ramelteon is used instead 16 mg 
at bedtime, twice the FDA-approved dose is recommended.
Conclusion
Once breast cancer has metastasized to bone, liver, or lungs, 
the prognosis becomes poor. No current treatment has a reli-
able and robust disease control rate at that point.
Animal study of the complete ABC7 regimen would be 
advisable. Based on clinical experience with these drugs 
individually and in pairs in general medical practice, the 
predicted safety and tolerability of the ABC7 regimen should 
be safe. As a further safety measure, the ABC7 drugs should 
be added one at a time at weekly intervals, thereby catching 
any unwanted interactions early and the offending drug more 
easily identified.
In this article, we propose that seven common and already 
FDA-approved drugs, such as agomelatine (or ramelteon), 
metformin, pirfenidone, propranolol, quetiapine, ribavi-
rin, and rifabutin, can have the ability to reduce EMT and 
breast cancer cell tumorigenesis. These ancillary drugs have 
demonstrated that attributes that we have reason to believe 
will inhibit EMT and enhance capecitabine’s efficacy. The 
predicted safety and tolerability of the ABC7 regimen is 
good. A clinical trial is warranted given the fatal outcome 
of metastatic breast cancer as things now stand.
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stimulating factor; GTP, guanosine-5′-triphosphate; HER2, 
human epidermal growth factor receptor 2; Hh, hedgehog; 
HR, hormone receptor; HR+, hormone receptor positive; 
HR−, hormone receptor negative; IGF1R, insulin-like growth 
factor type 1 receptor; IL-6, interleukin-6; IMPDH, inosine 
monophosphate dehydrogenase; MCLCK, myosin light-
chain kinase; MEMMAT regimen, metronomic and targeted 
anti-angiogenesis therapy regimen; MET, mesenchymal-to-
epithelial transition; MNK, MAP kinase-interacting kinase; 
mTOR, mammalian target of rapamycin; MTZ regimen, 
minocycline telmisartan and zoledronic acid regimen; m7G, 
7-methylguanosine; NAD+, nicotinamide adenine dinucleo-
tide; NCATS, National Center for Advancing Translational 
Sciences; NK, natural killer; NSCLC, non-small cell lung 
cancer; OPG, osteoprotegerin; PDGF, platelet-derived growth 
factor; PR, progesterone receptor; RANK, receptor activa-
tor of nuclear factor-κB; RANKL, RANK ligand; ROCK-1, 
rho-associated protein kinase; ROS, reactive oxygen species; 





SEEM, selective estrogen enzyme modulator; SERM, selec-
tive estrogen receptor modulator; TGF-beta, transforming 
growth factor-beta; Th, T helper; TNBC, triple-negative 
breast cancer; ZO-1, zonula occludens-1.
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